Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 29 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

14%

2 of 14 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (4)
P 1 (3)
P 2 (3)
P 3 (2)
P 4 (1)

Trial Status

Completed14
Unknown8
Recruiting4
Not Yet Recruiting2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT07288918Not ApplicableNot Yet RecruitingPrimary

The Effect of Education on Quality of Life, Adherence to Immunosuppressive Therapy and Symptom Control in Organ Transplant Patients

NCT01123187Not ApplicableCompleted

Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

NCT05556720Phase 3Active Not Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT06950398Phase 2Not Yet RecruitingPrimary

Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers

NCT04687865RecruitingPrimary

Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)

NCT06652919RecruitingPrimary

Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients

NCT02314949RecruitingPrimary

Leuven Tolerogenic Protocol for Intestinal Transplantation

NCT03997253Not ApplicableRecruitingPrimary

Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management

NCT06121804UnknownPrimary

Immunosuppressants to Postoperative Infection and Death

NCT01283295UnknownPrimary

Immune Monitoring and Assay Development in Organ Transplant Recipients

NCT01633424CompletedPrimary

The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)

NCT05685888CompletedPrimary

Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation

NCT00213304Phase 3CompletedPrimary

The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation

NCT03699839Phase 2Completed

Reducing the Burden of Influenza After Solid-Organ Transplantation

NCT00904579Completed

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00565773Phase 2CompletedPrimary

Belatacept Post Depletional Repopulation to Facilitate Tolerance

NCT00149981UnknownPrimary

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

NCT03861962UnknownPrimary

Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level

NCT02852902Completed

Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.

NCT01515072Not ApplicableCompletedPrimary

Remote Ischemic Preconditioning in Neurological Death Organ Donors

Scroll to load more

Research Network

Activity Timeline